Dr. Reddy's 42nd AGM Concludes: All Resolutions Passed, Final Dividend Declared
Dr. Reddy's Laboratories Limited held its 42nd AGM on July 23, 2026. All resolutions passed, including the adoption of FY26 financial statements and declaration of an ₹8 final dividend per share. Key appointments and auditor re-appointments were confirmed.
The outcome of an AGM, including dividend declaration and director re-appointments, is a routine but important event for shareholders, impacting their returns and the company's governance structure.
The announcement details the successful conclusion of the AGM with all resolutions passed, including the declaration of a final dividend and re-appointments, indicating positive corporate governance and shareholder alignment.
Dr. Reddy's Laboratories Limited held its 42nd Annual General Meeting (AGM) today, July 23, 2026, via Video Conferencing (VC) and Other Audio-Visual Means (OAVM). The meeting successfully transacted all business as stated in the AGM notice dated May 12, 2026.
During the AGM, shareholders approved the Audited Financial Statements (Standalone and Consolidated) for the financial year ended March 31, 2026. A final dividend of ₹8 per equity share was declared for the same financial year. Key personnel appointments and re-appointments were also confirmed. Mr. K Satish Reddy was re-appointed as a Director, and Dr. K P Krishnan was re-appointed as an Independent Director for a second five-year term. Mr. Srikanth Velamakanni was appointed as an Independent Director.
Furthermore, M/s. Deloitte Haskins & Sells, LLP were appointed as the Statutory Auditors for a period of five consecutive years, and their remuneration was fixed. The remuneration payable to cost auditors, M/s Sagar & Associates, for the Financial Year ending March 31, 2027, was also ratified.
The meeting commenced at 11:00 AM IST and concluded at 12:52 PM IST. The consolidated Scrutinizer's Report confirmed that all resolutions were passed by the requisite majority. The remote e-voting period was from July 19, 2026, to July 22, 2026, with an additional e-voting facility available during the AGM.
What to do with a filing like this
Dr. Reddy's Laboratories Limited filed this with the NSE as a statutory disclosure, categorised under agm. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Dr. Reddy's Laboratories Limited. Read the original for the full detail.